NASDAQ:VIVE Viveve Medical (VIVE) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free VIVE Stock Alerts $0.0002 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.11Volume1,400 shsAverage Volume3,699 shsMarket Capitalization$2,144.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media Get Viveve Medical alerts: Email Address Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Viveve Medical Stock (NASDAQ:VIVE)Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.Read More VIVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIVE Stock News HeadlinesFebruary 23, 2024 | benzinga.comViveve Medical Stock (OTC:VIVE), Analyst Ratings, Price Targets, PredictionsJuly 29, 2023 | seekingalpha.comVIVE Viveve Medical, Inc.March 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …July 25, 2023 | finance.yahoo.comInMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve PatentsJune 14, 2023 | uk.finance.yahoo.comVIVE - Viveve Medical, Inc.February 24, 2023 | finance.yahoo.comViveve Medical, Inc. (VIVE)January 17, 2023 | msn.comWhy Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionJanuary 17, 2023 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:January 17, 2023 | seekingalpha.comViveve crashes ~60% as company decides to delist, explore sale after trial failsJanuary 17, 2023 | finance.yahoo.comViveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary IncontinenceJanuary 17, 2023 | finance.yahoo.comViveve Medical Seeks Strategic Alternatives After Failed Stress Urinary Incontinence TrialJanuary 17, 2023 | investorplace.comWhy Is Viveve Medical (VIVE) Stock Down 69% Today?December 29, 2022 | insidermonkey.comViveve Medical, Inc. (NASDAQ:VIVE) Q3 2022 Earnings Call TranscriptDecember 15, 2022 | finance.yahoo.comViveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedDecember 1, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceDecember 1, 2022 | finance.yahoo.comViveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceNovember 13, 2022 | finance.yahoo.comViveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comViveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comViveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022October 25, 2022 | finance.yahoo.comGlobal Cosmetic Gynecology Market Report to 2027 - Featuring Alma Laser, Lutronic, Viveve Medical and Venus Concept Among OthersOctober 13, 2022 | forbes.comViveve MedicalOctober 4, 2022 | finanznachrichten.deViveve Medical, Inc.: Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceOctober 4, 2022 | finance.yahoo.comViveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary IncontinenceSeptember 27, 2022 | finance.yahoo.comViveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial ReadoutSeptember 22, 2022 | finance.yahoo.comViveve to Participate in Ladenburg Thalmann Healthcare ConferenceSee More Headlines Receive VIVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:VIVE Previous SymbolOTCMKTS:PLCSD CUSIPN/A CIK879682 Webwww.viveve.com Phone(720) 696-8100Fax720-696-8199Employees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares10,720,000Free Float10,110,000Market Cap$2,144.00 OptionableNot Optionable Beta0.06 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Jim B. Robbins (Age 60)Senior VP of Finance & Administration and Principal Accounting & Financial Officer Comp: $386.94kMs. Deborah Ann Jorn M.B.A. (Age 66)Senior Advisor to the CEO & Director Comp: $35kMr. Martin Kerber P.E.Vice President of Research, Development & OperationsMs. Jeannie SwindleSenior Director of Corporate CommunicationsMr. Jeff SinclairVice President of International SalesMr. Gary KaiserVice President of Global MarketingMs. Lori McMillanVice President of Human ResourcesMs. Suzon D. Lommel (Age 66)Senior Vice President of Regulatory & Quality Affairs More ExecutivesKey CompetitorsOncoSec MedicalNASDAQ:ONCSQKaleido BiosciencesNASDAQ:KLDOGenocea BiosciencesNASDAQ:GNCAQGenocea BiosciencesNASDAQ:GNCANabriva TherapeuticsNASDAQ:NBRVView All Competitors VIVE Stock Analysis - Frequently Asked Questions How have VIVE shares performed in 2024? Viveve Medical's stock was trading at $0.0002 at the start of the year. Since then, VIVE stock has increased by 0.0% and is now trading at $0.0002. View the best growth stocks for 2024 here. How were Viveve Medical's earnings last quarter? Viveve Medical, Inc. (NASDAQ:VIVE) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.09. The firm earned $1.62 million during the quarter. During the same quarter last year, the firm posted ($2.60) EPS. What other stocks do shareholders of Viveve Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX). When did Viveve Medical IPO? (VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager. How do I buy shares of Viveve Medical? Shares of VIVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIVE) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viveve Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.